Antiretroviral therapy reduces neurodegeneration in HIV infection

AIDS

Volumn 29, Issue 3, 2015, Pages 323-330

  Bryant, Alex K ^a   Ellis, Ronald J ^a,b   Umlauf, Anya ^a   Gouaux, Ben ^a   Soontornniyomkij, Virawudh ^a   Letendre, Scott L ^a   Achim, Cristian L ^a,c   Masliah, Eliezer ^a,b,c   Grant, Igor ^a   Moore, David J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiretroviral therapy; Brain; HIV; Mild cognitive impairment; Neurodegenerative disorders

Indexed keywords

MICROTUBULE ASSOCIATED PROTEIN; SYNAPTOPHYSIN; ANTIRETROVIRUS AGENT; MAP2 PROTEIN, HUMAN; SYP PROTEIN, HUMAN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYNAPTOSOME; VIRUS LOAD; AUTOPSY; BRAIN CORTEX; COMPLICATION; HIV INFECTIONS; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; AUTOPSY; CEREBRAL CORTEX; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEURODEGENERATIVE DISEASES; RETROSPECTIVE STUDIES; SYNAPTOPHYSIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84927774923     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000553     Document Type: Article

References (16)

1. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010; 75:2087-2096.
2. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8:33-44.
3. Munoz-Morena JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008; 24:1301-1307.
4. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIVpositive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
5. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
6. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16:101-114.
7. Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 2014; 28:493-501.
8. Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey CL, Cherner M, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006; 20:879-887.
9. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26:759-778.
10. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 2012; 26:894-908.
11. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
12. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, et al. Dendritic injury is a pathologic substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 1997; 42:963-972.
13. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 1999; 9:209-217.
14. Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho ES, et al. HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1991; 1:143-152.
15. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80:27-38.
16. Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 2014; 20:39-53.